SUPG Supergen, Inc. (MM)

DUBLIN, Calif., Sept. 8 /PRNewswire-FirstCall/ -- SuperGen, Inc. (NASDAQ:SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced that Michael Molkentin, Chief Financial Officer, and Michael V. McCullar, Ph.D., Vice President of Drug Discovery Operations, are scheduled to co-present at the Merriman 5th Annual Investor Summit on Monday, September 15, 2008 at the Mark Hopkins Hotel in San Francisco. SuperGen's presentation at the Merriman Investor Summit is scheduled to begin at 8:30 a.m. PDT (11:30 a.m. EDT). A live webcast of the presentation will be available on the investor relations section of the Company's Web site at http://www.supergen.com/. A webcast replay of the presentation will be available shortly following the live event. About SuperGen Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery and development of novel cancer therapies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com/ . Contacts: SuperGen, Inc. Timothy L. Enns SVP, Corporate Communications & Business Development Tel: (925) 560-0100 Email: Mary M. Vegh Manager, Investor Relations Tel: (925) 560-2845 E-mail: Dorland Global Public Relations Michael Beckerich (Media) Tel: (212) 677-7632 DATASOURCE: SuperGen, Inc. CONTACT: Timothy L. Enns, SVP, Corporate Communications & Business Development, +1-925-560-0100, , and Mary M. Vegh, Manager, Investor Relations, +1-925-560-2845, , both of SuperGen, Inc.; or Michael Beckerich (Media), of Dorland Global Public Relations, +1-212-677-7632, Web site: http://www.supergen.com/

Copyright